Gadolinium Toxicity

Recent Viewpoints

Enter your email address to follow this blog and receive notifications of new posts by email.

Viewpoint Categories

Monthly Archives

The viewpoints presented here include Gadolinium Toxicity news and thoughts about various aspects of living with the effects of Gadolinium Toxicity.  They may just be one person’s idea or an experience that happened to them.  These viewpoints are important to share, because someone looking at them from a different viewpoint may be able to tie some things together in a way that we did not see.

Study Reports Gadolinium Clearance Times for 135 Contrast MRI Cases including Agent Administered for 63 Unconfounded Cases

On December 5, 2018, Hubbs Grimm and Sharon Williams, coauthors of GadoliniumToxicity.com, released their fifth research paper on gadolinium retention from Gadolinium-based Contrast Agents (GBCAs) administered for contrast-enhanced MRIs.  The paper is titled Gadolinium Clearance Times for 135 Contrast MRI Cases and includes the contrast agents for the unconfounded cases.

Drawing on the contrast MRI history and 24-hour gadolinium urine testing results that have been received from members of the MRI-Gadolinium-Toxicity Support Group on Yahoo, the study reports retrospectively on 135 cases with 218 urine test results, including 63 unconfounded cases with 81 test results.  The participants all had normal kidney function and report having symptoms of gadolinium toxicity.  The results reported are dramatic and involve all linear and macrocyclic GBCAs currently in use in the United States.

About the Gadolinium Clearance Time Report

In addition to reporting on additional cases received since our previous paper in 2017, we now report the contrast agents received with each unconfounded case.  Analysis of the these cases produced trend lines over time that indicate typical gadolinium found in 24-hour urine testing for each of the agents including Dotarem, Gadavist, Magnevist, MultiHance, Omniscan, OptiMARK, and ProHance.  The graphs and tables provide helpful information for both patients and medical practitioners trying to understand their test results.  The analysis of clearance times for each agent is presented on a separate page.

The results show that all agents, both linear and macrocyclic, do not clear from the body in a few days as most patients are told.  None of the test results in the first 2.5 months following a contrast-enhanced MRI was within the reference range used by Mayo Clinic Laboratories.  It should be noted that the contrast agent and test result information presented is from people who believe they are suffering symptoms of gadolinium toxicity since their contrast-enhanced MRI.  It is not known whether the clearance times presented would also apply to individuals who are not symptomatic.

The complete set of test results, without any data that would identify patients, is available to other researchers upon request.

With the evidence provided that clearance times are much longer for all of the agents than expected by medical practitioners, the authors present five recommendations for needed actions by medical professionals, other researchers, government agencies, and contrast agent manufacturers.

Final Thoughts

We want to thank members of the MRI-Gadolinium-Toxicity Support Group for their willingness to share their test results and other information with us.  Our papers would not be possible without their continued support.

We urge patients, clinicians, and researchers to read the entire report and share as appropriate with your families, caregivers, and colleagues.

Read the Gadolinium Clearance Times for 135 Contrast MRI Cases Report

Hubbs Grimm and Sharon Williams

Gadolinium Toxicity – Let’s not make the same mistake again

An Editorial by Hubbs Grimm
August 2018

(A pdf of this Editorial is available for download)

I want to talk about the unfortunate results of the early studies of gadolinium toxicity that defined NSF and the parallels I see today in the effort to define Gadolinium Deposition Disease (GDD).  I will also propose an alternative view of how to describe gadolinium toxicity in a way that reflects what we currently know and do not know that will recognize all patients who have been affected by retained gadolinium.

Before I begin, I want to be clear that I believe all those who have contributed in the past and those who are contributing today are doing so with the best of intentions and working from the basis of their experience and perspective.  But that does not mean that the result or proposals are necessarily best for meeting the needs of the people who are suffering from the toxic effects of gadolinium.

(more…)

Gadolinium Toxicity: If not NSF, then what is it?

Editorial by Sharon Williams
August 2018

(A pdf of this Editorial is available for download)

What difference does a name make?  Evidently, when you are naming a disease it can make a huge difference.  The name can limit the scope of medical research, and when it comes to gadolinium, it has the potential to exclude other patient populations who have been exposed to the same toxic metal.

In 1997, when a group of patients on dialysis developed what appeared to be a new skin disorder, it was called Nephrogenic Fibrosing Dermopathy (NFD).  When researchers later learned that the problem went well beyond the patients’ skin and caused a systemic disease process, the name was changed to Nephrogenic Systemic Fibrosis (NSF).  The word “nephrogenic” in the name caused doctors and researchers to focus on people with severe renal disease.  At the beginning, that made sense since the problem only had been seen in patients with end-stage renal disease (ESRD).  Later we learned more about the cause.

In 2006, nine years after NSF/NFD was first diagnosed, the connection was made between NSF and gadolinium-based contrast agents (GBCAs) administered for MRIs.  Even though impaired kidney function did not cause NSF, the focus remained on the “N” or nephrogenic part of NSF.  Patients with normal kidney function were being overlooked; however, they were not unaffected by retained gadolinium from GBCAs.

(more…)

Gadolinium Toxicity – Status and Direction – August 2018

The two of us, Sharon Williams and Hubbs Grimm, have been working together on gadolinium toxicity related issues since 2012 and this website since 2014.  Since it affects us and our many new friends personally, coming to agreement on our “message” has not always been easy but we have done it.

Recently, out of frustration with lack of progress on matters related to gadolinium toxicity from MRI contrast agents, we wanted to do a post that was both reflective of where the medical community has been on this issue and where we believe it ought to go.  While we had similar ideas, we differed in how we wanted to convey the message.  So, we each worked on our own editorial and then we helped each other with the final copy as we have done many times in the past.

Tomorrow we will be posting two editorials about Gadolinium Toxicity.  While our approaches are different, this is not a dispute between us or an attempt to decide which is right and which is wrong.  Instead, it is two people, working together with great respect for each other, expressing their thoughts in an important discussion about something that affects countless other people.  We invite industry representatives to contribute to this discussion.

We hope you will read both editorials and take time to consider the important points we make.

Sharon’s editorial is titled, “Gadolinium Toxicity: If not NSF, then what is it?
Hubbs’ editorial is titled, “Gadolinium Toxicity – Let’s not make the same mistake again

Sharon Williams and Hubbs Grimm
Coauthors of The Lighthouse Project

%d bloggers like this: